Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Mineralys Therapeutics Inc fell by 38.40m. Cash Flow from Financing totalled 203.25m or -- of revenues. In addition the company used 81.17m for operations while cash used for investing totalled 160.47m.
Cash flow per share | -2.75 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.84 |
---|---|
Tangible book value per share | 5.84 |
More ▼
Balance sheet in USDView more
Current ratio | 11.20 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼